{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:21:54Z","timestamp":1789924914748,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04084-7","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T09:02:33Z","timestamp":1723280553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"24","author":[{"given":"Michael","family":"Butzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Aronitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Tantakoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanatan","family":"Shreay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Drudge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"issue":"37","key":"4084_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626.","journal-title":"Eur Heart J"},{"issue":"25","key":"4084_CR2","first-page":"e558","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2020;142(25):e558\u2013631.","journal-title":"Circulation"},{"issue":"9","key":"4084_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","volume":"85","author":"H Kitaoka","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, Fujino N, Higo T, Isobe M, Kamiya C, et al. JCS\/JHFS 2018 Guideline on the diagnosis and treatment of Cardiomyopathies. Circ J. 2021;85(9):1590\u2013689.","journal-title":"Circ J"},{"issue":"3","key":"4084_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jjcc.2022.09.015","volume":"81","author":"N Terasaka","year":"2023","unstructured":"Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: a nationwide medical claims database study. J Cardiol. 2023;81(3):316\u201322.","journal-title":"J Cardiol"},{"issue":"13","key":"4084_CR5","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/jcm11133898","volume":"11","author":"M Butzner","year":"2022","unstructured":"Butzner M, Rowin E, Yakubu A, Seale J, Robertson LA, Sarocco P, Maron MS. Clinical characteristics and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy treated in a range of settings in the United States. J Clin Med. 2022;11(13):3898.","journal-title":"J Clin Med"},{"issue":"1","key":"4084_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","volume":"4","author":"E Zaiser","year":"2020","unstructured":"Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"4084_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","volume":"24","author":"SS Jain","year":"2021","unstructured":"Jain SS, Li SS, Xie J, Sutton MB, Fine JT, Edelberg JM, Gao W, Spertus JA, Cohen DJ. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2021;24(1):1115\u201323.","journal-title":"J Med Econ"},{"issue":"39","key":"4084_CR8","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379.","journal-title":"Eur Heart J"},{"issue":"4","key":"4084_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):372\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"4084_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-med-042220-021539","volume":"73","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: new concepts and therapies. Annu Rev Med. 2022;73:363\u201375.","journal-title":"Annu Rev Med"},{"issue":"4","key":"4084_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):390\u2013414.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"4084_CR12","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","volume":"117","author":"MS Maron","year":"2016","unstructured":"Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Card. 2016;117(10):1651\u20134.","journal-title":"Am J Card"},{"issue":"17","key":"4084_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/heartjnl-2021-320181","volume":"108","author":"JRW Brownrigg","year":"2022","unstructured":"Brownrigg JRW, Leo V, Rose J, Low E, Richards S, Carr-White G, Elliott PM. Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study. Heart. 2022;108(17):1383.","journal-title":"Heart"},{"issue":"3","key":"4084_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.mayocp.2023.09.009","volume":"99","author":"S Karim","year":"2024","unstructured":"Karim S, Chahal CAA, Sherif AA, Khanji MY, Scott CG, Chamberlain AM, Geske JB, Ommen SR, Gersh BJ, Somers VK, et al. Re-evaluating the incidence and prevalence of clinical hypertrophic cardiomyopathy: an epidemiological study of Olmsted County, Minnesota. Mayo Clin Proc. 2024;99(3):362\u201374.","journal-title":"Mayo Clin Proc"},{"key":"4084_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2021.08.024","volume":"159","author":"M Butzner","year":"2021","unstructured":"Butzner M, Maron M, Sarocco P, Rowin E, Teng CC, Tan H, Stanek E, Robertson L. Clinical diagnosis of hypertrophic cardiomyopathy over time in the United States (a population-based claims analysis). Am J Cardiol. 2021;159:107\u201312.","journal-title":"Am J Cardiol"},{"key":"4084_CR16","doi-asserted-by":"crossref","unstructured":"Schultze M, Zema C, Carroll R, Hurst M, Borchert J, Zhong Y, Krause T, Bluhmki T, Partington H, Osman F et al. Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany. Eur Heart J 2022, 43(Supplement_2).","DOI":"10.1093\/eurheartj\/ehac544.1747"},{"issue":"5","key":"4084_CR17","doi-asserted-by":"publisher","first-page":"e0196612","DOI":"10.1371\/journal.pone.0196612","volume":"13","author":"D Husser","year":"2018","unstructured":"Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J, Hindricks G, Bollmann A. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. PLoS ONE. 2018;13(5):e0196612.","journal-title":"PLoS ONE"},{"issue":"7","key":"4084_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655\u201368.","journal-title":"N Engl J Med"},{"issue":"2","key":"4084_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.amjmed.2015.07.035","volume":"129","author":"E Argulian","year":"2016","unstructured":"Argulian E, Sherrid MV, Messerli FH. Misconceptions and facts about hypertrophic cardiomyopathy. Am J Med. 2016;129(2):148\u201352.","journal-title":"Am J Med"},{"issue":"8","key":"4084_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1253\/circj.CJ-20-0524","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Kubo T, Doi YL. Hypertrophic cardiomyopathy - A heterogeneous and lifelong disease in the real world. Circ J. 2020;84(8):1218\u201326.","journal-title":"Circ J"},{"issue":"4","key":"4084_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery Risk Development in (Young) adults. Circulation. 1995;92(4):785\u20139.","journal-title":"Circulation"},{"issue":"8","key":"4084_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0002-9149(94)90337-9","volume":"73","author":"BJ Maron","year":"1994","unstructured":"Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Card. 1994;73(8):577\u201380.","journal-title":"Am J Card"},{"key":"4084_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/CLEP.S139300","volume":"9","author":"P Magnusson","year":"2017","unstructured":"Magnusson P, Palm A, Branden E, M\u00f6rner S. Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes. Clin Epidemiol. 2017;9:403\u201310.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"4084_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11897-021-00523-0","volume":"18","author":"M Zampieri","year":"2021","unstructured":"Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B, Castelli G, Cappelli F, Stef\u00e0no P, Marchionni N, et al. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep. 2021;18(4):169\u201379.","journal-title":"Curr Heart Fail Rep"},{"issue":"7","key":"4084_CR25","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1053\/j.jvca.2021.07.024","volume":"36","author":"DR Addis","year":"2022","unstructured":"Addis DR, Townsley MM. Perioperative implications of the 2020 American Heart Association\/American College of Cardiology Guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a focused review. J Cardiothorac Vasc Anesth. 2022;36(7):2143\u201353.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"8","key":"4084_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","volume":"82","author":"C Palandri","year":"2022","unstructured":"Palandri C, Santini L, Argir\u00f2 A, Margara F, Doste R, Bueno-Orovio A, Olivotto I, Coppini R. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889\u2013912.","journal-title":"Drugs"},{"issue":"11","key":"4084_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M, Sehnert AJ. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170(11):741\u20138.","journal-title":"Ann Intern Med"},{"issue":"10253","key":"4084_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369.","journal-title":"Lancet"},{"issue":"10","key":"4084_CR29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8(10):968\u201377.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"4084_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"4084_CR31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D\u00fcngen H-D, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390(20):1849\u201361.","journal-title":"N Engl J Med"},{"issue":"8Supplement","key":"4084_CR32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0735-1097(23)00768-4","volume":"81","author":"S Saberi","year":"2023","unstructured":"Saberi S, Abraham TP, Choudhury L, Owens AT, Tower-Rader A, Rader F, Pavia PG, Olivotto I, Coats C, Fifer MA, et al. Long-term efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(8Supplement):324\u2013324.","journal-title":"J Am Coll Cardiol"},{"key":"4084_CR33","unstructured":"A phase 3, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of aficamten compared to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (MAPLE-HCM) https:\/\/www.clinicaltrials.gov\/study\/NCT05767346"},{"issue":"3","key":"4084_CR34","first-page":"369","volume":"28","author":"M Beinfeld","year":"2022","unstructured":"Beinfeld M, Wasfy JH, Walton S, Sarker J, Nhan E, Rind DM, Pearson SD. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value. J Manag Care Spec Pharm. 2022;28(3):369\u201375.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"4084_CR35","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2217\/fca-2020-0242","volume":"17","author":"E Hutt","year":"2021","unstructured":"Hutt E, Nissen SE, Desai MY. Unmet needs in the treatment of hypertrophic cardiomyopathy. Future Cardiol. 2021;17(7):1261\u20137.","journal-title":"Future Cardiol"},{"key":"4084_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","volume":"180","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Dearani JA, Smedira NG, Schaff HV, Wang S, Rastegar H, Ralph-Edwards A, Ferrazzi P, Swistel D, Shemin RJ, et al. Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel. Am J Cardiol. 2022;180:124\u201339.","journal-title":"Am J Cardiol"},{"issue":"1","key":"4084_CR37","first-page":"E8","volume":"34","author":"S Yandrapalli","year":"2022","unstructured":"Yandrapalli S, Harikrishnan P, Andries G, Aronow WS, Panza JA, Naidu SS. Differences in short-term outcomes and hospital-based resource utilization between septal reduction strategies for hypertrophic obstructive cardiomyopathy. J Invasive Cardiol. 2022;34(1):E8\u201313.","journal-title":"J Invasive Cardiol"},{"issue":"4","key":"4084_CR38","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","volume":"50","author":"K Talari","year":"2020","unstructured":"Talari K, Goyal M. Retrospective studies - utility and caveats. J R Coll Physicians Edinb. 2020;50(4):398\u2013402.","journal-title":"J R Coll Physicians Edinb"},{"key":"4084_CR39","volume-title":"StatPearls [Internet]","author":"J Bello","year":"2022","unstructured":"Bello J, Pellegrini MV. Mavacamten. StatPearls [Internet]. edn. Florida: StatPearls Publishing; 2022."},{"issue":"1","key":"4084_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","volume":"25","author":"J Xie","year":"2022","unstructured":"Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. J Med Econ. 2022;25(1):51\u20138.","journal-title":"J Med Econ"},{"issue":"13","key":"4084_CR41","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.3390\/ijms22137218","volume":"22","author":"C St\u0103tescu","year":"2021","unstructured":"St\u0103tescu C, Enachi \u0218, Ureche C, \u021a\u0103poi L, Anghel L, \u0218alaru D, Ple\u0219oianu C, Bostan M, Marcu D, Ovanez Balasanian M, et al. Pushing the limits of medical management in HCM: a review of current pharmacological therapy options. Int J Mol Sci. 2021;22(13):7218.","journal-title":"Int J Mol Sci"},{"key":"4084_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2020.07.036","volume":"318","author":"M Ciabatti","year":"2020","unstructured":"Ciabatti M, Fumagalli C, Beltrami M, Vignini E, Martinese L, Tomberli A, Zampieri M, Bertini A, Carrassa G, Marchi A, et al. Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2020;318:94\u2013100.","journal-title":"Int J Cardiol"},{"issue":"6 Suppl","key":"4084_CR43","first-page":"S118","volume":"27","author":"P Taddei-Allen","year":"2021","unstructured":"Taddei-Allen P. Hypertrophic cardiomyopathy considerations for the managed care pharmacist. Am J Manag Care. 2021;27(6 Suppl):S118\u201325.","journal-title":"Am J Manag Care"},{"key":"4084_CR44","first-page":"100089","volume":"13","author":"M Butzner","year":"2022","unstructured":"Butzner M, Maron M, Sarocco P, Teng C-C, Stanek E, Tan H, Robertson L. Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population. Am Heart J Plus. 2022;13:100089.","journal-title":"Am Heart J Plus"},{"issue":"2","key":"4084_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","volume":"11","author":"AT Owens","year":"2022","unstructured":"Owens AT, Sutton MB, Gao W, Fine JT, Xie J, Naidu SS, Desai NR. Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study. Cardiol Ther. 2022;11(2):249\u201367.","journal-title":"Cardiol Ther"},{"issue":"12","key":"4084_CR46","doi-asserted-by":"crossref","first-page":"E866","DOI":"10.25270\/jic\/22.00150","volume":"34","author":"M Butzner","year":"2022","unstructured":"Butzner M, Maron MS, Sarocco P, Teng CC, Stanek E, Tan H, Robertson LA. Costs and healthcare resource utilization for obstructive hypertrophic cardiomyopathy with septal reduction therapy. J Invasive Cardiol. 2022;34(12):E866\u201372.","journal-title":"J Invasive Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04084-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T15:41:25Z","timestamp":1732635685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4084"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04084-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EA, HC, KT, and CD are paid employees of EVERSANA\u2122, which was contracted by Cytokinetics Incorporated to work on this project. MB and SS are paid employees of Cytokinetics Incorporated, which is the manufacturer of aficamten.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}